Brain-Training Firm, FTC Settle

San Francisco-based Lumos Labs, creator of the brain-training program Lumosity, will pay $2 million to settle deceptive-advertising charges raised by the US Federal Trade Commission.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

PEXELSThe company behind the popular brain-training program Lumosity will pay the US Federal Trade Commission (FTC) $2 million in a settlement related to deceptive advertising charges, the agency announced yesterday (January 5). As part of the settlement, San Francisco-based Lumos Labs is to notify Lumosity customers of the FTC action and provide instructions to cancel auto-renewal billing. (The program is available for purchase through monthly or lifetime subscriptions.)

“Lumosity preyed on consumers’ fears about age-related cognitive decline, suggesting their games could stave off memory loss, dementia, and even Alzheimer’s disease,” Jessica Rich, director of the FTC’s Bureau of Consumer Protection, said in the statement. “But Lumosity simply did not have the science to back up its ads.” (See “Opinion: Can the Brain Be Trained?”)

In a statement sent to reporters (via Reuters), Lumos Labs said the FTC charges were tied to “marketing language that has been discontinued.” STAT News reported that the company said its focus “will not change.”

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Tracy Vence

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide